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Gamma-hydroxybutyrate (GHB) and topiramate - clinically relevant drug 
interaction suggested by a case with increased GHB plasma concentration 
 
To the Editor: 
A 52-year-old woman was hospitalized for worsening chronic cluster headache 
refractory to all guideline-based medical and invasive treatments. Based on class IV 
evidence [1] she had regularly taken high-dose gamma-hydroxybutyrate (GHB, or also 
sodium oxybate; Xyrem®) 4.5 g twice-nightly at 11 pm and 3 am for the last 6 years. This was 
the only drug that markedly improved her nocturnal headache episodes and insomnia. As an 
additional therapeutic effort topiramate (Topamax®) was started with a single dose of 25 mg 
at 6 pm, and GHB was taken thereafter as usual. The next morning the patient developed 
confusion, followed by intermittent myoclonic jerks, miosis, and a rapid onset of coma with a 
Glasgow Coma Scale (GCS) score of 3 at 8:00 am. Pulse, blood pressure, respiratory rate, 
pulse oximetry, electrocardiogram and laboratory values including electrolytes and blood 
glucose were unremarkable. A blood sample for GHB determination using gas 
chromatography-mass spectrometry was obtained at 8 am, and its plasma concentration was 
259 mg/L. One hour later electroencephalography (EEG) showed intermittent bifrontal theta 
activity, a pattern described during sedation with GHB [2]. At 1 pm the patient awoke from 
coma and rapidly recovered within a few hours. Topiramate was stopped, but GHB continued 
as before. Two days later GHB plasma concentration was measured again at 8 am and was 
91 mg/L. 
In the presented case, with concomitant topiramate GHB concentration 5 hours after 
its second dose was 2.8 times higher than without topiramate, and 1.8 times higher than a 
peak concentration of 142 mg/L that would be expected 0.5 to 2 hours after the second dose 
according to Xyrem®’s product information. In contrast, the patient had taken topiramate 
without concomitant GHB in the past without problems. Together with the rapid onset but 
	   3 
short duration of the otherwise unexplained coma and the EEG findings, this observation is 
highly suggestive of a drug-induced coma due to a pharmacokinetic interaction between 
GHB and topiramate. GHB has a short half-life of about 30 min [3], and metabolism via GHB-
dehydrogenase is its main route of elimination [4]. In-vitro studies demonstrated inhibition of 
GHB-dehydrogenase by the antiepileptic drugs valproate and ethosuximide [4], but according 
to Xyrem®’s product information no interaction studies with antiepileptics were performed in 
humans. Alternatively, changes in the bioavailability of GHB or other unknown mechanisms 
of interaction are theoretically possible. Furthermore, topiramate increases GABA activity at 
its neuroreceptors, and an additional pharmacodynamic interaction must therefore also be 
considered. 
In light of the increasing therapeutic as well as illicit use of GHB as well as of newer 
antiepileptic drugs, possible interactions should be evaluated in formal pharmacokinetic 
studies. Meanwhile we suggest using such combinations only with great care. 
 
References 
1 Khatami R, Tartarotti S, Siccoli MM, Bassetti CL, Sandor PS (2011) Long-term 
efficacy of sodium oxybate in 4 patients with chronic cluster headache. Neurology 77 
(1): 67-70 
2 Entholzner E, Mielke L, Pichlmeier R, Weber F, Schneck H (1995) EEG changes 
during sedation with gamma-hydroxybutyric acid. Der Anaesthesist 44 (5): 345-350 
3 Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, 
Watson DE (2004) Pharmacokinetics and excretion of gamma-hydroxybutyrate 
(GHB) in healthy subjects. Journal Anal Toxicol 28 (8): 625-630 
4 Hechler V, Ratomponirina C, Maitre M (1997) gamma-Hydroxybutyrate conversion 
into GABA induces displacement of GABAB binding that is blocked by valproate and 
ethosuximide. J Pharmacol Exp Ther 281 (2): 753-760 
 
	  
